Nationally Recognized Tumor Neurosurgeon Joins
Capital Institute for Neurosciences

Capital Health has added another nationally recognized neurosurgeon to its roster of neuroscience experts as part of the Capital Institute for Neurosciences. Dr. Arlan Mintz, a nationally recognized neurosurgeon specializing in neurosurgical oncology, is now providing advanced care for patients with brain and spine tumors.

Capital Institute for Neurosciences has steadily been growing since its inception in 2008. Now a national leader in neurosciences, the Institute is the largest program in the State of New Jersey and attracts patients from around the world.  

Dr. Arlan Mintz Announcement Photo

Arlan H. Mintz, MD, MSc, FRCS (C), FACS

Director, Neuro-Oncology

Surgical Director, CyberKnife, Capital Health

Dr. Mintz performs both open and minimally invasive surgical options for patients with primary tumors, both benign and malignant in nature, as well as metastatic brain tumors. He specializes in the use of CyberKnife® stereotactic radiosurgery, providing a comprehensive approach that can be tailored to each patient’s condition. Dr. Mintz performed one of the first surgical procedures in the world using High Definition Fiber Tractography (HDFT) mapping to preserve critical areas of brain function during complex tumor surgery.

“What attracted me to this program and the Capital Institute for Neurosciences is its level of comprehensiveness and the resources dedicated to it,” said Dr. Mintz. “The commitment to bringing experts on board in various sub-specialties, with very focused expertise, is a serious commitment on the hospital’s part to establish a world class program for patients with brain conditions.”

Dr. Mintz, director of Neurosurgical Oncology at Capital Health and surgical director of Radiosurgery, joined the healthcare system’s Capital Institute for Neurosciences from the University of Pittsburgh where he was an associate professor of neurological surgery at the University of Pittsburgh School of Medicine and director of University of Pittsburgh Medical Center’s Adult Neurosurgical Oncology program, one of the leading neurosurgery programs in the country. 

Dr. Mintz is board certified in neurological surgery in both the United States and Canada and specializes in the treatment of tumors. He treats patients with both primary tumors, benign and malignant in nature, and metastatic brain tumors that are the result of cancer that has spread from another location in the body. In determining surgical options for his patients, Dr. Mintz offers comprehensive treatment options including awake craniotomies using cortical mapping, minimally invasive corridor directed surgery using surgical ports that allow the removal of tumors with the least amount of disruption to surrounding brain tissue, and radiosurgery using CyberKnife and TrueBeam. The use of image-guided microscopic and endoscopic port surgery, combined with advanced white matter imaging using tractography and functional MRI, allows Capital neurosurgeons to safely access deep seated tumors.

Dr. Mintz received his medical degree from McMaster University in Ontario, Canada and completed his neurosurgery residency at the University of Ottawa. Dr. Mintz also holds Master of Science degrees in neurophysiology and clinical epidemiology. He completed his surgical internship at McMaster University and his neurosurgical training at Ottawa General and Civic Hospital and Wellesley Central Hospital in Toronto.

Dr. Mintz is a fellow of the American College of Surgeons. He is a member of the Congress of Neurological Surgeons Tumor Section, the Society of Neuro-Oncology, the North American Skull Base Society, CyberKnife Society, the Radiation Therapy Oncology Group, International Stereotactic Radiosurgery Society, the Royal College of Physicians and Surgeons of Canada and is a fellow of the American Association of Neurological Surgeons.

Dr. Mintz has published numerous academic articles and has lectured internationally and nationally in addition to being an active researcher in the area of brain tumors.

Back to top